Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia

Acute Myeloid leukemia (AML) is a clinically heterogeneous disease with a 5-year overall survival of 32% between 2012 to 2018. The above number severely dwindles with age and adverse risk of disease, presenting opportunities for new drug development and is an area of dire unmet need. Basic science and clinical investigators across the world have been working on many new and old molecule formulations and combination strategies to improve outcomes in this disease. In this review, we discuss select promising novel agents in various stages of clinical development for patients with AML.

Automated summary

Acute Myeloid Leukemia (AML) has a 5-year overall survival rate of 32% from 2012 to 2018, and the number decreases significantly with age and adverse disease risk. This provides opportunities for new drug development and addresses an urgent unmet need. Researchers worldwide are focusing on developing new and existing molecule formulations and combination strategies to improve outcomes in AML patients. This review discusses promising novel agents in different stages of clinical development for AML patients.